A venture capital firm based in the US is focused on companies in the healthcare field with a preference for innovative technology-based companies in Medtech, Diagnostics, and Digital Health. For medical devices, the firm will invest in both PMA and 510k devices and prefers to see some clinical validation. The firm is stage agnostic but most often first invests $3-8M in Series A-C and reserves funds for follow-on investments. Most of the firm’s investments have been in the US and Israel, but the firm is open to investing globally.

The firm invests in companies with medical device, diagnostics and digital health technologies, focusing on innovative companies that can revolutionize their space. The firm favors technology-based products, such as genomics-based diagnostics or high-tech medical devices. Within digital health, the firm is fairly open, but has an interest in companies developing tools for clinical trials and other products developed for payer networks or Big Pharma. The firm is also interested in digital health technologies for hard-to-reach patient populations, such as those suffering from mental health disorders or substance abuse. While fairly opportunistic with regards to indication, the firm is particularly interested in technologies in the COPD, pulmonary hypertension, orthopedic and neurological space as well as products using ablation to treat pain.

The firm wants to see a strong CEO and Board when making investments. While often a not a lead investor, the firm is very active and will frequently take a Board seat after investing. The firm is looking to lead more investments when investing from their third fund.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A private investment firm based in the US launched a fund about 10 years ago to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The firm focuses on early-stage digital health projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A family office investment firm is focused on early-stage Biotech/Medtech investments primarily in Switzerland. The firm’s biggest investment in a single company is CHF 5M thus far, but the size of investment could vary. The firm looks for companies located around the globe, with a preference in Switzerland or Europe. The firm is actively seeking new investment opportunities.

The firm looks to invest 70% in Therapeutics, 10% in Medical Devices, 10% Digital Health and 10% in Diagnostics. In Therapeutic areas, the firm might invest half in early-stage and another half in later-stage. The firm is opportunistic in indications and willing to consider orphan indications. The firm seeks technologies that could fill unmet medical needs.

The firm has no specific requirements on companies. The firm currently acts as lead investors for two companies, and has represented in five boards. The firm might take a board seat depends on applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A strategic healthcare venture investment representing multiple health systems as LPs has decades of investment experience. The firm makes equity investments into early- to late-stage companies with additional capital reserved for follow on financings. The firm prefers to invest in USA-based companies.

The firm is currently looking for new opportunities in the Medical Device, Diagnostic, Healthcare IT and Healthcare Services spaces. The firm considers all classes of medical devices and focuses on device companies in the pre-commercial stage. The firm has a preference for platform technologies and companies whose products are already commercialized. The firm’s Healthcare IT and Healthcare Services investments are typically in the commercial or growth stages. The firm invests in privately held healthcare companies. The firm looks to invest in companies with a strong management team who can demonstrate relevant experience, depth and capability to build and scale the business and attract customers. The firm typically requests a Board seat or Board observation rights for each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A firm with multiple offices throughout Western Europe makes biotech and medtech investments from an evergreen fund. The firm typically makes initial investments of EUR 7-15M at the Series A or B stage, and may commit EUR 25M over the life of an investment. The firm invests mainly across Europe, and aims to make at least 4 life science investments per year, with 80% in the therapeutics space.

The firm invests across the biotech and medtech sectors. Within the biotech sector, the firm prefers to invest in platform technologies, multi asset and single asset companies, and will invest as early as the preclinical stage. The firm will consider any therapeutic area, and has an interest in orphan drugs. The firm prefers opportunities that do not require very large clinical trials. For medical devices, the firm prefers to invest in companies with products with a global potential, that are close to acquiring a CE Mark and/or US approval and that are preparing commercialization. The firm is also interested in enabling technologies such as next-gen PCR and lab equipment. The firm does not invest in company-creation opportunities: the firm prefers to work with companies that already have high-quality management teams that have proven themselves through past success in the life science industry, and who have a strong network within the industry. The firm also considers the company’s capital efficiency, future capital needs, and the strength of the company’s prior investment syndicate. The firm prefers to lead or co-lead investments, and is a highly active investor at a portfolio company’s board level.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm headquartered in the US is currently on their second fund, and the typical check size is flexible, with a typical first check for coming at the seed through series A stage between $1M-5M. The firm is open to both leading or following the investments, but prefers to lead at the seed stage.  The firm focuses on companies located in the US.

The firm is looking for new investment opportunities in sectors focused on applied biology and chemistry, including the therapeutics and diagnostics sectors as well as sustainability, synthetic biology, agtech, and other industrial sectors. The firm is opportunistic in terms of sub-sectors and indications, including all phases of development for therapeutics and various use-cases of synthetic biology. The firm is not typically interested in healthcare services or healthcare IT.

The firm invests in companies in the US and likes to see second or third time entrepreneurs, however the firm will back bold first time entrepreneurs with compelling technologies. The firm is open to both leading or following the investment, and could seek a board seat in certain deals.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A San Francisco based venture platform founded in 2016 focuses on early stage healthcare companies. The firm currently has 34 companies in their portfolio with 4 exits. The firm invests in all 4 life science sectors and the typical check size ranges from $100K – 500K and typically helps fill out existing rounds once there is a lead investor in-place. The firm generally seeks to make investments into emerging life science companies in Pre-Seed, Seed and Series A stages. The firm is US focused in terms of geographic preference, but will occasionally look outside of the US.

The firm invests across all life science verticals and is open to all 4 sectors. The firm looks for novel technologies in biotech, medtech, digital health therapeutics, and diagnostics. In terms of biotech companies, the firm focuses on biotechnology platforms rather than single asset biotech companies. The firm is agnostic to both subsector and indication and is open to both pre-clinical therapeutic companies as well as all three stages of medical devices.

The firm is open to all types of management teams, with a goal to democratize who gets funding in the life science space. The firm is looking for diversity in the management team to combine ideas and skill set. The firm prefers to co-invest rather than lead.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.